Cannabis use disorder
|Cannabis use disorder|
|Other names||Cannabis addictions, marijuana addiction|
Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment.
Signs and symptoms
Cannabis use and abuse has symptoms that affect behavior, physical, cognitive, and psychosocial aspects of a person’s life. Symptoms include agitation, bloodshot eyes, challenges in problem solving, and paranoia.
Cannabis use is associated with comorbid mental health problems, such as mood and anxiety disorders, and discontinuing cannabis use is difficult for some users. Psychiatric comorbidities are often present in dependent cannabis users including a range of personality disorders.
The use of cannabis at a young age such as the teenage years, can have serious impacts on depression and anxiety in youth and later in life. There is evidence that cannabis use during adolescence, at a time when the brain is still developing, may have deleterious effects on neural development and later cognitive functioning. The brain is not completely developed until a person reaches the age range of 22-27. Excessive use of marijuana can cause harm to this development. Based on annual survey data, 7% of high school seniors that smoke daily function at a lower rate in school than students that do not. The sedating and anxiolytic properties of tetrahydrocannabinol (THC) in some users might make the use of cannabis an attempt to self-medicate personality or psychiatric disorders.
Prolonged cannabis use produces both pharmacokinetic changes (how the drug is absorbed, distributed, metabolized, and excreted) and pharmacodynamic changes (how the drug interacts with target cells) to the body. These changes require the user to consume higher doses of the drug to achieve a common desirable effect (known as a higher tolerance), reinforcing the body’s metabolic systems for eliminating the drug more efficiently and further downregulating cannabinoid receptors in the brain.
Cannabis users have shown decreased reactivity to dopamine, suggesting a possible link to a dampening of the reward system of the brain and an increase in negative emotion and addiction severity.
Cannabis users can develop tolerance to the effects of THC. Tolerance to the behavioral and psychological effects of THC has been demonstrated in adolescent humans and animals. The mechanisms that create this tolerance to THC are thought to involve changes in cannabinoid receptor function.
According to the National Cannabis Prevention and Information Centre in Australia, a sign of cannabis dependence is that an individual spends noticeably more time than the average recreational user recovering from the use of or obtaining cannabis. For some, using cannabis becomes a substantial and disruptive part of an individual’s life and he or she may exhibit difficulties in meeting personal obligations or participating in important life activities, preferring to use cannabis instead. People who are cannabis dependent have the inability to stop or decrease using cannabis on their own. One study has shown that between 2001-2002 and 2012-2013, the use of marijuanna in the US doubled.
Cannabis dependence develops in about 9% of users, significantly less than that of heroin, cocaine, alcohol, and prescribed anxiolytics, but slightly higher than that for psilocybin, mescaline, or LSD. Of those who use cannabis daily, 10–20% develop dependence.
Cannabis withdrawal symptoms can occur in one half of patients in treatment for cannabis use disorders. These symptoms include dysphoria (anxiety, irritability, depression, restlessness), disturbed sleep, gastrointestinal symptoms, and decreased appetite. Most symptoms begin during the first week of abstinence and resolve after a few weeks. According to a study in the U.S., 12.1% of heavy cannabis users showed cannabis withdrawal as defined by the DSM-5, and this was associated with significant disability as well as mood, anxiety and personality disorders.
Cannabis addiction is often due to prolonged and increasing use of the drug. Increasing the strength of the cannabis taken and an increasing use of more effective methods of delivery often increase the progression of cannabis dependency. It can also be caused by being prone to becoming addicted to substances, which can either be genetically or environmentally acquired.
Certain factors are considered to heighten the risk of developing cannabis dependence and longitudinal studies over a number of years have enabled researchers to track aspects of social and psychological development concurrently with cannabis use. Increasing evidence is being shown for the elevation of associated problems by the frequency and age at which cannabis is used, with young and frequent users being at most risk.
The main factors in Australia, for example, related to a heightened risk for developing problems with cannabis use include frequent use at a young age; personal maladjustment; emotional distress; poor parenting; school drop-out; affiliation with drug-using peers; moving away from home at an early age; daily cigarette smoking; and ready access to cannabis. The researchers concluded there is emerging evidence that positive experiences to early cannabis use are a significant predictor of late dependence and that genetic predisposition plays a role in the development of problematic use.
High risk groups
A number of groups have been identified as being at greater risk of developing cannabis dependence and, in Australia, for example, have been found to include adolescent populations, Aboriginal and Torres Strait Islanders and people suffering from mental health conditions.
Young people are at greater risk of developing cannabis dependence because of the association between early initiation into substance use and subsequent problems such as dependence, and the risks associated with using cannabis at a developmentally vulnerable age.
Cannabis use disorder is recognized in the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which also added cannabis withdrawal as a new condition.
In the 2013 revision for the DSM-5, DSM-IV abuse and dependence were combined into cannabis use disorder. The legal problems criterion (from cannabis abuse) has been removed, and the craving criterion was newly added, resulting in a total of 11 criteria. These are: hazardous use, social/interpersonal problems, neglected major roles, withdrawal, tolerance, used larger amounts/longer, repeated attempts to quit/control use, much time spent using, physical/psychological problems related to use, activities given up and craving. For a diagnosis of DSM-5 cannabis use disorder, at least 2 of these criteria need to be present in the last 12 month period. Additionally, three severity levels have been defined: mild (2-3 criteria), moderate (4-5 criteria) and severe (six or more criteria) cannabis use disorder.
As a time and cost saving alternative to extensive diagnostic interviews, several short scales for the screening for cannabis-related problems have been developed. Among the most frequently used screeners are the Cannabis Use Disorders Identification Test (CUDIT), Severity of Dependence Scale (SDS), Cannabis Abuse Screening Test (CAST) and Problematic Use of Marijuana (PUM).
Clinicians differentiate between casual users who have difficulty with drug screens, and daily heavy users, to a chronic user who uses multiple times a day. In the US, as of 2013[update], cannabis is the most commonly identified illicit substance used by people admitted to treatment facilities. Demand for treatment for cannabis use disorder increased internationally between 1995 and 2002. In the United States, the average adult who seeks treatment has consumed cannabis for over 10 years almost daily and has attempted to quit six or more times.
Treatment options for cannabis dependence are far fewer than for opiate or alcohol dependence. Most treatment falls into the categories of psychological or psychotherapeutic, intervention, pharmacological intervention or treatment through peer support and environmental approaches. Screening and brief intervention sessions can be given in a variety of settings, particularly at doctor’s offices, which is of importance as most cannabis users seeking help will do so from their general practitioner rather than a drug treatment service agency.
The most commonly accessed forms of treatment in Australia are 12-step programmes, physicians, rehabilitation programmes, and detox services, with inpatient and outpatient services equally accessed. In the EU approximately 20% of all primary admissions and 29% of all new drug clients in 2005, had primary cannabis problems. And in all countries that reported data between 1999–2005 the number of people seeking treatment for cannabis use increased.
Psychological intervention includes cognitive behavioral therapy (CBT), motivational enhancement therapy (MET), contingency management (CM), supportive-expressive psychotherapy (SEP), family and systems interventions, and twelve-step programs.
Evaluations of Marijuana Anonymous programs, modelled on the 12-step lines of Alcoholics Anonymous and Narcotics Anonymous, have shown small beneficial effects for general drug use reduction.[medical citation needed] In 2006, the Wisconsin Initiative to Promote Healthy Lifestyles implemented a program that helps primary care physicians identify and address marijuana use problems in patients.
As of 2012, there is no medication that has been proven effective for treating cannabis use disorder; research is focused on three treatment approaches: agonist substitution, antagonist, and modulation of other neurotransmitter systems. More broadly, the goal of medication therapy for cannabis use disorder centers around targeting the stages of the addiction: acute intoxication/binge, withdrawal/negative affect, and preoccupation/anticipation.
For the treatment of the withdrawal/negative affect symptom domain of cannabis use disorder, medications may work by alleviating restlessness, irritable or depressed mood, anxiety, and insomnia. Bupropion, which is a norepinephrine–dopamine reuptake inhibitor, has been studied for the treatment of withdrawal with largely poor results. Atomoxetine has also shown poor results, and is as a norepinephrine reuptake inhibitor, though it does increase the release of dopamine through downstream effects in the prefrontal cortex (an area of the brain responsible for planning complex tasks and behavior). Venlafaxine, a serotonin–norepinephrine reuptake inhibitor, has also been studied for cannabis use disorder, with the thought that the serotonergic component may be useful for the depressed mood or anxious dimensions of the withdrawal symptom domain. While venlafaxine has been shown to improve mood for people with cannabis use disorder, a clinical trial in this population actually found worse cannabis abstinence rates compared to placebo. It’s worth noting that venlafaxine is sometimes poorly tolerated, and infrequent use or abrupt discontinuation of its use can lead to withdrawal symptoms from the medication itself, including irritability, dysphoria, and insomnia. It is possible that venlafaxine use actually exacerbated cannabis withdrawal symptoms, leading people to use more cannabis than placebo to alleviate their discomfort. Mirtazapine, which increases serotonin and norepinephrine, has also failed to improve abstinence rates in people with cannabis use disorder.
People sometimes use cannabis to cope with their anxiety, and cannabis withdrawal can lead to symptoms of anxiety. Buspirone, a serotonin 1A receptor (5-HT1A) agonist, has shown limited efficacy for treating anxiety in people with cannabis use disorder, though there may be better efficacy in males than in females. Fluoxetine, a selective serotonin reuptake inhibitor, has failed to show efficacy in adolescents with both cannabis use disorder and depression. SSRIs are a class of antidepressant drugs that are also used for the treatment of anxiety disorders, such as generalized anxiety disorder. Vilazodone, which has both SSRI and 5-HT1A agonism properties, also failed to increase abstinence rates in people with cannabis use disorder.
Studies of divalproex have found no significant benefit, though some studies have found mixed results. Baclofen, a GABA-B receptor agonist and antispasmodic medication, has been found to reduce cravings but without a significant benefit towards preventing relapse or improving sleep. Zolpidem, a GABA-A receptor agonist and “Z-hypnotic” medication, has shown some efficacy in treating insomnia due to cannabis withdrawal, though there is a potential for misuse. Entacapone was well-tolerated and decreased cannabis cravings in a trial on a small number of patients. Topiramate, an antiepileptic drug, has shown mixed results in adolescents, reducing the volume of cannabis consumption without significantly increasing abstinence, with somewhat poor tolerability. Gabapentin, an indirect GABA modulator, has shown some preliminary benefit for reducing cravings and cannabis use.
The agonist substitution approach is one that draws upon the analogy of the success of nicotine replacement therapy for nicotine addiction. Dronabinol, which is synthetic THC, has shown benefit in reducing cravings and other symptoms of withdrawal, though without preventing relapse or promoting abstinence. Combination therapy with dronabinol and the alpha 2 adrenergic receptor agonist lofexidine have shown mixed results, with possible benefits towards reducing withdrawal symptoms. However, overall, the combination of dronabinol and lofexidine is likely not effective for the treatment of cannabis use disorder. Nabilone, a synthetic THC analogue, has shown benefits in reducing symptoms of withdrawal such as difficulty sleeping, and decreased overall cannabis use. Despite its psychoactive effects, the slower onset of action and longer duration of action of nabilone make it less likely to be abused than cannabis itself, which makes nabilone a promising harm reduction strategy for the treatment of cannabis use disorder. The combination of nabilone and zolpidem has been shown to decrease sleep-related and mood-related symptoms of cannabis withdrawal, in addition to decreasing cannabis use. Nabiximols, a combined THC and cannabidiol (CBD) product that is formulated as an oral (buccal) spray, has been shown to improve withdrawal symptoms without improving abstinence rates. Oral CBD has not shown efficacy in reducing the signs or symptoms of cannabis use, and likely has no benefit in cannabis use withdrawal symptoms. The CB-1 receptor antagonist rimonabant has shown efficacy in reducing the effects of cannabis in users, but with a risk for serious psychiatric side effects.
Naltrexone, a mu opioid receptor antagonist, has shown mixed results for cannabis use disorder—both increasing the subjective affects of cannabis when given acutely, but potentially decreasing the overall use of cannabis with chronic administration. N-acetylcysteine (NAC) has shown some limited benefit in decreasing cannabis use in adolescents, though not with adults. Lithium, a mood stabilizer, has shown mixed results for treating symptoms of cannabis withdrawal, but is likely ineffective. Quetiapine, a second-generation antipsychotic, has been shown to treat cannabis withdrawal related insomnia and decreased appetite at the expense of exacerbating cravings. Oxytocin, a neuropeptide that the body produces, has shown some benefit in reducing the use of cannabis when administered intranasally in combination with motivational enhancement therapy sessions, though the treatment effect did not persist between sessions.
Barriers to treatment
Research that looks at barriers to cannabis treatment frequently cites a lack of interest in treatment, lack of motivation and knowledge of treatment facilities, an overall lack of facilities, costs associated with treatment, difficulty meeting program eligibility criteria and transport difficulties.[dubious ]
Cannabis is one of the most widely used drugs in the world. In the United States, between 42% and 49% of people have used cannabis, an estimated 9% of those who use cannabis develop dependence.[needs update] 34.8% of Australians aged 14 years and over have used cannabis one or more times in their life. In the U.S., cannabis is the most commonly identified illicit substance used by people admitted to treatment facilities. Most of these people were referred there by the criminal justice system. 16% of admittees either went on their own, or were referred by family or friends.
In the European Union (data as available in 2018, information for individual countries was collected between 2012 and 2017), 26.3% of adults aged 15–64 used cannabis at least once in their lives, and 7.2% used cannabis in the last year. The highest prevalence of cannabis use among 15 to 64 years old in the EU was reported in France, with 41.4% having used cannabis at least once in their life, and 2.17% used cannabis daily or almost daily. Among young adults (15–34 years old), 14.1% used cannabis in the last year.
Among adolescents (15–16 years old) in a European school based study (ESPAD), 16% of students have used cannabis at least once in their life, and 7% (boys: 8%, girls: 5%) of students had used cannabis in the last 30 days.
Globally, 22.1 million people (0.3% of the worlds population) were estimated to suffer from cannabis dependence.
A 2014 Cochrane Collaboration review did not find sufficient data to evaluate the effectiveness of any medication for cannabis use disorder, though the authors commented that most available therapies are likely ineffective.
- National Institute on Drug Abuse (2014), The Science of Drug Abuse and Addiction: The Basics
- Gordon AJ, Conley JW, Gordon JM (December 2013). “Medical consequences of marijuana use: a review of current literature”. Current Psychiatry Reports (Review). 15 (12): 419. doi:10.1007/s11920-013-0419-7. PMID 24234874.
- “Cannabis Symptoms”. Timberline Knolls. Retrieved 7 May 2018.
- Danovitch I, Gorelick DA (June 2012). “State of the art treatments for cannabis dependence”. The Psychiatric Clinics of North America (Review). 35 (2): 309–26. doi:10.1016/j.psc.2012.03.003. PMC 3371269. PMID 22640758.
- Dervaux, Alain (December 2012). “Cannabis: Use and dependence”. La Presse Médicale.
- NCPIC. “Cannabis and young people | NCPIC”. ncpic.org.au. Archived from the original on 9 March 2016. Retrieved 30 September 2016.
- McLaren, J, Mattick, R P., Cannabis in Australia Use, supply, harms, and responses Monograph series No. 57 Report prepared for: Drug Strategy Branch Australian Government Department of Health and Ageing. National Drug and Alcohol Research Centre University of New South Wales, Australia.
- “Excessive use of Cannabis”. Centers for Disease Control and Prevention. Retrieved 7 May 2018.
- E.B., Robertson. “Information on Cannabis Addiction”. National Institute on Drug Abuse. Retrieved 7 May 2018.
- Clinical Textbook of Addictive Disorders, Marijuana, David McDowell, page 169, Published by Guilford Press, 2005 ISBN 1-59385-174-X.
- Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB (June 2012). “Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers”. Molecular Psychiatry. 17 (6): 642–9. doi:10.1038/mp.2011.82. PMC 3223558. PMID 21747398.
- Madras BK (August 2014). “Dopamine challenge reveals neuroadaptive changes in marijuana abusers”. Proceedings of the National Academy of Sciences of the United States of America. 111 (33): 11915–6. Bibcode:2014PNAS..11111915M. doi:10.1073/pnas.1412314111. PMC 4143049. PMID 25114244.
- González S, Cebeira M, Fernández-Ruiz J (June 2005). “Cannabinoid tolerance and dependence: a review of studies in laboratory animals”. Pharmacology Biochemistry and Behavior. 81 (2): 300–18. doi:10.1016/j.pbb.2005.01.028. PMID 15919107.
- Maldonado R, Berrendero F, Ozaita A, Robledo P (May 2011). “Neurochemical basis of cannabis addiction”. Neuroscience. 181: 1–17. doi:10.1016/j.neuroscience.2011.02.035. PMID 21334423.
- “Alcohol vs Cannabis 2015”. National Cannabis Prevention and Information. Retrieved 17 April 2015.
- “Marijuana use disorder is common and often untreated”. National Institutes of Health (NIH). 4 March 2016. Retrieved 3 April 2019.
- Wilkie G, Sakr B, Rizack T (March 2016). “Medical Marijuana Use in Oncology: A Review”. JAMA Oncology. 2 (5): 670–675. doi:10.1001/jamaoncol.2016.0155. PMID 26986677.
- Budney AJ, Roffman R, Stephens RS, Walker D (December 2007). “Marijuana dependence and its treatment”. Addiction Science & Clinical Practice. 4 (1): 4–16. doi:10.1151/ascp07414. PMC 2797098. PMID 18292704.
- Borgelt LM, Franson KL, Nussbaum AM, Wang GS (February 2013). “The pharmacologic and clinical effects of medical cannabis”. Pharmacotherapy (Review). 33 (2): 195–209. doi:10.1002/phar.1187. PMID 23386598.
- Livne O, Shmulewitz D, Lev-Ran S, Hasin DS (February 2019). “DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults”. Drug and Alcohol Dependence. 195: 170–177. doi:10.1016/j.drugalcdep.2018.09.005. PMC 6359953. PMID 30361043.
- Coffey1, Carlin2, Lynskey3, Li4, Patton5, Carolyn1, John B.2, Michael3, Ning4, George C.5 (1 April 2003). “Adolescent precursors of cannabis addiction: Findings from the Victorian Adolescent Health Cohort Study”. The British Journal of Psychiatry. 182 (4): 330–336. doi:10.1192/bjp.182.4.330.CS1 maint: Multiple names: authors list (link)
- “DrugFacts: Marijuana”. National Institute on Drug Abuse. Retrieved 20 July 2015.
- Copeland J, Gerber S, Swift W (December 2004). Evidence-based answers to cannabis questions a review of the literature. National Drug and Alcohol Research Centre University of New South Wales, A report prepared for the Australian National Council on Drugs.
- “Proposed Revision | APA DSM-5”. Dsm5.org. Retrieved 20 April 2011.
- “DSM-5 Now Categorizes Substance Use Disorder in a Single Continuum” (PDF). American Psychiatric Association. 17 May 2013. Retrieved 12 December 2013.
- Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF (August 2013). “DSM-5 criteria for substance use disorders: recommendations and rationale”. The American Journal of Psychiatry. 170 (8): 834–51. doi:10.1176/appi.ajp.2013.12060782. PMC 3767415. PMID 23903334.
- Piontek D, Kraus L, Klempova D (December 2008). “Short scales to assess cannabis-related problems: a review of psychometric properties”. Substance Abuse Treatment, Prevention, and Policy. 3: 25. doi:10.1186/1747-597X-3-25. PMC 2636780. PMID 19055741.
- Substance Abuse and Mental Health Services Administration, Office of Applied Studies. (2003). Emergency department trends from the drug abuse warning network, final estimates 1995–2002, DAWN Series: D-24, DHHS Publication No. (SMA) 03-3780.
- Nielsen, S; Gowing, L; Sabioni, P; Le Foll, B (28 January 2019). “Pharmacotherapies for cannabis dependence”. The Cochrane Database of Systematic Reviews. 1: CD008940. doi:10.1002/14651858.CD008940.pub3. PMC 6360924. PMID 30687936.
- Degenhardt L, Hall W, Lynskey M (2000). Cannabis use and mental health among Australian adults: Findings from the National Survey of Mental Health and Well-being, NDARC Technical Report No. 98. Sydney: National Drug and Alcohol Research Centre, University of New South Wales.
- Copeland J, Swift W (April 2009). “Cannabis use disorder: epidemiology and management”. International Review of Psychiatry (Review). 21 (2): 96–103. doi:10.1080/09540260902782745. PMID 19367503.
- EMCDDA (2007). Annual report 2007: The state of the drugs problem in Europe. Luxembourg: Office for Official Publications of the European Communities.
- “With Support From Collaborative, Primary Care Practices Identify and Address Behavioral Health Issues, Reducing Binge Drinking, Marijuana Use, and Depression Symptoms”. Agency for Healthcare Research and Quality. 8 May 2013. Retrieved 10 May 2013.
- Zehra, A; Burns, J; Liu, CK; Manza, P; Wiers, CE; Volkow, ND; Wang, GJ (December 2018). “Cannabis Addiction and the Brain: a Review”. Journal of Neuroimmune Pharmacology. 13 (4): 438–452. doi:10.1007/s11481-018-9782-9. PMC 6223748. PMID 29556883.
- Brezing, CA; Levin, FR (January 2018). “The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal”. Neuropsychopharmacology. 43 (1): 173–194. doi:10.1038/npp.2017.212. PMC 5719115. PMID 28875989.
- Fava, GA; Benasi, G; Lucente, M; Offidani, E; Cosci, F; Guidi, J (2018). “Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review”. Psychotherapy and Psychosomatics. 87 (4): 195–203. doi:10.1159/000491524. PMID 30016772.
- “Generalised anxiety disorder – NICE Pathways”. pathways.nice.org.uk. NICE. Retrieved 13 April 2019.
- Treloar C, Holt M (2006). “Deficit models and divergent philosophies: Service providers’ perspectives on barriers and incentives to drug treatment”. Drugs: Education Prevention and Policy. 13 (4): 367–382. doi:10.1080/09687630600761444.
- Treloar C, Abelson J, Cao W, Brener L, Kippax S, Schultz L, Schultz M, Bath N (2004). Barriers and incentives to treatment for illicit drug users. Monograph Series 53. Canberra: Department of Health and Ageing, National Drug Strategy.
- Gates P, Taplin S, Copeland J, Swift W, Martin G (2008). Barriers and Facilitators to Cannabis Treatment. National Cannabis Prevention and Information Centre, University of New South Wales, Sydney.
- “6 facts about marijuana”.
- Marshall K, Gowing L, Ali R, Le Foll B (17 December 2014). “Pharmacotherapies for cannabis dependence”. The Cochrane Database of Systematic Reviews. 12 (12): CD008940. doi:10.1002/14651858.CD008940.pub2. PMC 4297244. PMID 25515775.
- “Drug Info”. Australian Drug Foundation. Archived from the original on 25 April 2011.
- “Treatment Episode Data Set (TEDS)2001 – 2011. National Admissions to Substance Abuse Treatment Services” (PDF). samhsa.gov. Substance Abuse and Mental Health Services Administration. Retrieved 17 April 2015.
- “Statistical Bulletin 2018 — prevalence of drug use | www.emcdda.europa.eu”. www.emcdda.europa.eu. Retrieved 5 February 2019.
- “Summary | www.espad.org”. www.espad.org. Retrieved 5 February 2019.
- Degenhardt, Louisa; Charlson, Fiona; Ferrari, Alize; Santomauro, Damian; Erskine, Holly; Mantilla-Herrara, Ana; Whiteford, Harvey; Leung, Janni; Naghavi, Mohsen; Griswold, Max; Rehm, Jürgen; Hall, Wayne; Sartorius, Benn; Scott, James; Vollset, Stein Emil; Knudsen, Ann Kristin; Haro, Josep Maria; Patton, George; Kopec, Jacek; Carvalho Malta, Deborah; Topor-Madry, Roman; McGrath, John; Haagsma, Juanita; Allebeck, Peter; Phillips, Michael; Salomon, Joshua; Hay, Simon; Foreman, Kyle; Lim, Stephen; et al. (December 2018). “The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016”. The Lancet. Psychiatry. 5 (12): 987–1012. doi:10.1016/S2215-0366(18)30337-7. PMC 6251968. PMID 30392731.